Abstract
Translational medicine is one of the critical components to overcome the impediments within the objectives of Predictive Preventive and
Personalized Medicine. Identification of molecular mechanisms underlying subclinical stages of T1D pathogenesis is a key to detection of new
biomarkers and development of drugs of new generation. To date, this is getting possible because of practical application of recent advances
in translational medicine and translation of fundamentals in genomics, proteomics and metabolomics into clinical methods of preventive
immunocorrection/immunomodulation and regeneration of beta-cells in Langerhans’ islands. In this paper, we describe novel immune and
cell methods to prevent T1D, discuss the specifics in their application at subclinical stages and propose new approaches to modulate immune
status in patients with T1D and regeneration of insulin-producing beta-cells by mesenchymal stem cells.
Keywords
Authors and affiliations
D.S. Kostyushev (1,9), S.V. Krynskiy (1,3), P. Pozzili (4), G.N. Filatova (2), M. von Herrath (5,6), M.А. Paltsev (7–9), S.V. Suchkov (1,2,9)
1 -I.M. Sechenov First Moscow State Medical University, Moscow, Russia; 2 -Moscow State Medical-Stomatological University,
Moscow, Russia; 3 -M.N. Emanuel Institute of Biochemical Physics of RAS, Moscow, Russia; 4 -Department of Endocrinology and Diabetes, University Campus Bio-Medico, Rome, Italy; 5 -Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, University of California in San Diego (UCSD), San Diego, CA, USA; 6 -R&D Division, Novo Nordisk Company (Denmark);
7 -«Kurchatov Institute» National Research Center; 8 -PFUR Translation Medicine Institute, Moscow, Russia;
9 -European Predictive-Preventive and Personalized Medicine Association (EPMA), Brussels, EU